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We describe a rubella outbreak that occurred in 
Romania between September 2011 and December 
2012. During this period 24,627 rubella cases, 41.1% 
(n=10,134) of which female, were notified based on 
clinical criteria, and a total of 6,182 individuals were 
found serologically positive for IgM-specific rubella 
antibody. The median age of notified cases was 18 
years (range: <1–65) and the most affected age group 
15 to 19 years (n=16,245 cases). Of all notified cases, 
24,067 cases (97.7%) reported no history of vaccina-
tion. Phylogenetic analysis of 19 sequences (739 nucle-
otides each), from 10 districts of the country revealed 
that the outbreak was caused by two distinct rubella 
virus strains of genotype 2B, which co-circulated with 
both temporal and geographical overlap. In addition to 
the 6,182 IgM-positive rubella cases, 28 cases of con-
genital rubella syndrome (CRS) were identified, includ-
ing 11 neonatal deaths and one stillbirth. The outbreak 
underscores the need to encourage higher vaccina-
tion uptake in the population, particularly in women 
of reproductive age, and to strengthen epidemiologi-
cal and laboratory investigations of suspected rubella 
cases. Genetic characterisation of wild-type rubella 
virus is an essential component to enhance surveil-
lance and here we report rubella virus sequences from 
Romania.
Introduction
Rubella virus (RuV), the sole member of the Rubivirus 
genus in the Togaviridae family, is a positive strand 
RNA virus with a non-segmented genome of ca 9,762 
nucleotides (nt). The genome encodes two non-struc-
tural (P90 and P150) and three structural (virion) pro-
teins (the capsid and 2 envelope glycoproteins, E2 
and E1). A 739-nt region between nt 8,731 and 9,469 
within the E1 glycoprotein is the standard genotyping 
window for RuV [1,2]. Based on phylogenetic analysis 
of sequences of the structural protein coding region, 
two virus clades including a total of 13 genotypes, have 
been identified.
Infection with RuV generally leads to mild disease with 
symptoms that can include rash and low fever (<39°C) 
[3]. In pregnancy, however, RuV infection can cause 
miscarriages and serious birth defects including hear-
ing, vision, mental, and heart impairment, which are 
collectively known as congenital rubella syndrome 
(CRS). CRS occurs in up to 85% of children born to 
women with RuV infection during the first trimester of 
pregnancy [4]. In addition, CRS can lead to neonatal 
deaths in up to 30% of cases [5].
Laboratory investigation plays an important role in 
both diagnosis and surveillance of rubella and CRS, 
since clinical diagnosis is unreliable and up to 50% of 
infections are estimated to be subclinical [6]. Typically, 
rubella is diagnosed by RuV specific IgM, but in preg-
nancy additional testing such as IgG avidity may be 
necessary.
False-negative rubella IgM can occur when specimens 
are taken within the first three days post-rash onset 
while false-positive IgM can result from cross reac-
tions with rheumatoid factor or other viruses (such as 
parvovirus B19) [7,8]. In addition to serology, detection 
of viral RNA from nasopharyngeal swabs or oral fluid 
has been widely employed to confirm RuV infection. 
Moreover, polymerase chain reaction (PCR) can be 
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used to obtain genetic information about circulating 
wild-type viruses to investigate transmission events 
[9,10].
When the European Region of the World Health 
Organization (WHO) adopted the goal of eliminating 
endemic rubella and measles by the end of 2015, the 
two key strategies were to achieve and sustain high vac-
cination coverage (≥95%) with two doses of measles, 
mumps, and rubella (MMR) vaccine and to strengthen 
surveillance systems through rigorous investigation 
and laboratory confirmation of outbreak-related and 
sporadic cases [11]. Because phylogenetic analysis of 
RuV genotypes can help determine whether circulat-
ing RuV strains result from endemic transmission or 
importations, laboratory surveillance for rubella also 
included the molecular characterisation of viruses. 
In Romania, selective vaccination for rubella and mea-
sles was offered to adolescent girlsagedbetween 15 
and 18 years (birth cohorts 1980 – 1983) as part of a 
mass vaccination campaign following a nation-wide 
measles outbreak in 1998 [12]. In 2004, MMR vacci-
nation was introduced into the national immunisation 
programme with the first dose administered at 12 to 15 
months of age and the second dose at seven years-old, 
and a rubella-containing vaccine was offered to girls 
aged between 13 and 14 years until 2008 (birth cohort 
1994) [13]. Based on recent assessments of 18 month-
old children however, the estimated MMR vaccine (one 
dose) coverage has decreased from 96.5% in 2010 to 
89.3% in 2014 [14].
Rubella epidemics follow a 6 to 9 year cycle in the 
country. Between 2002 and 2003, Romania experi-
enced a large rubella outbreak with more than 115,000 
reported cases nationwide corresponding to an inci-
dence of 549 cases per 100,000 population, the high-
est incidence ever observed in the 24 prior years [12]. 
In 2011 and 2012, another rubella outbreak occurred, 
with an incidence of 20.6 cases per 100,000 popula-
tion in 2011 and 97.5 per 100,000 in 2012 [15]. This 
outbreak coincided with a measles outbreak, which 
took place between 2010 and 2013 and included 8,170 
notified cases [16]. Here we provide an overview on the 
2011 to 2012 rubella outbreak in Romania in terms of 
time, place and person, with a focus on laboratory and 
molecular analysis
Methods
Description of the surveillance systems
Since 1978 measles and rubella are statutorily notifi-
able diseases in Romania. Medical practitioners must 
report all possible measles or rubella cases to the 
regional public health authorities. The definition of a 
possible case in Romania concurs with the European 
Union (EU) case definition for possible cases and com-
prises any person with sudden onset of generalised 
maculopapular rash and at least one of the following 
five manifestations: cervical adenopathy, suboccipital 
adenopathy, post-auricular adenopathy, arthralgia, or 
arthritis [17,18]. 
A rubella surveillance system with case-based report-
ing with mandatory laboratory confirmation started in 
2010. IgM antibody detection by enzyme-linked immu-
nosorbent assay (ELISA) is the standard test for routine 
rubella surveillance recommended in the country [18]. 
In case of clusters/outbreaks, only five to ten sera from 
rubella possible cases are collected for testing [11,19]. 
Laboratory confirmation of cases in Romania is con-
ducted according to a national methodology. Except 
for pregnant women, cases in Romania are either lab-
oratory-confirmed by detecting rubella IgM antibod-
ies in serum samples, or a significant rise in rubella 
IgG antibody levels, or PCR detection of RuV genetic 
material in nasopharyngeal swabs. In pregnancy, a 
rubella-specific IgG avidity test is additionally used 
to confirm rubella infection in rubella IgM-positive 
patients. Moreover, pregnant women, who are known to 
have been exposed to rubella, are assessed for rubella 
specific IgM and IgG antibodies and for those found to 
be negative another sample of serum is requested after 
14 days to monitor IgM and/or IgG seroconversion [18].
As for measles, rubella surveillance is carried out 
among the general population, nationwide and all year 
round. The objectives of the surveillance are to facili-
tate the detection and laboratory confirmation of all 
possible sporadic cases, to identify chains of transmis-
sion and to investigate outbreaks. 
National surveillance for CRS, which is notifiable, was 
initiated in the year 2000 according to Romanian meth-
odology. The clinical criteria for CRS apply to any infant 
< 1 year of age or any stillborn and include at least 
two of the following conditions: cataract(s), congeni-
tal glaucoma, congenital heart disease, loss of hear-
ing, pigmentary retinopathy, or one of the above and 
either one of the subsequent manifestations: purpura, 
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splenomegaly, microcephaly, developmental delay, 
meningo-encephalitis, radiolucent bone disease, or 
jaundice that begins within 24 hours after birth [20].
Infants who meet the CRS clinical criteria are usually 
investigated for rubella-specific IgM and IgG antibod-
ies: a serum sample is collected as soon after birth as 
possible; for infants with IgM negative and IgG positive 
results, a second serum sample is required, according 
with the EU case definition [20].
Collection and processing of samples 
From September 2011 to December 2012, within the 
routine surveillance system, the Romanian Public 
Health Districts collected 9,627 serum samples from 
possible rubella cases for laboratory confirmation. 
These 9,627 samples corresponded to 9,615 possible 
rubella cases, including 314 pregnant women (whereby 
two serum samples were respectively received from 12 
pregnant women). 
During this time period 832 measles IgM-negative 
serum samples were also tested for rubella IgM. 
In accordance with the national surveillance for CRS, 
during the epidemic and post epidemic period (2012–
2013) 178 serum samples were collected from 137 
infants who met the clinical definition. 
From May 2011 to December 2012 (i.e. before and dur-
ing the outbreak), 68 nasopharyngeal (NP) swabs from 
sporadic and outbreak-related cases were collected in 
different districts. Necropsy samples were obtained 
from one CRS case. 
Sera, swabs and necropsy samples were transferred 
for testing to the Cantacuzino Institute laboratory. Sera 
were maintained at 2–8 °C until testing (maximum of 6 
days), then stored at –20 °C. The RNA extraction from 
swabs and the necropsy samples was done on the 
same day than the samples were received, followed by 
reverse transcription-(RT)-PCR detection, and in case 
of positive results by genotyping. The remaining swab 
samples and the extracted RNA were maintained at 
–70 °C.
Serological assays
Detection of RuV specific IgM antibodies was performed 
using the Enzygnost Anti-Rubella Virus/IgM anti-
body enzyme immunoassay (EIA; Siemens, Marburg, 
Germany) or the Rubella virus IgM micro-capture EIA 
(IBL International). The Euroimmun Anti-Rubella Virus 
IgG and Avidity ELISA kit (Lubeck, Germany) was used 
for IgG and avidity testing. According to the manufac-
turer, relative avidity indexes are interpreted as fol-
lows: < 40% indicates low avidity antibodies and > 60% 
indicates high avidity antibodies, with 40–60% con-
sidered as intermediate (high avidity excludes rubella 
infection within the last 4 to 6 weeks before sample 
collection).
RNA extraction from clinical specimens
In Romania, detection of RuV RNA or RNA extraction 
and subsequent genotyping were conducted only on NP 
swab samples and from necropsy samples (one case). 
As the number of swab samples collected during the 
outbreak was low (n=61), it was tested whether RNA 
could be obtained from IgM-positive serum samples 
that had been collected within three days after rash 
with a protocol used at the Centers for Disease Control 
and Prevention (CDC) in Atlanta, Georgia. Therefore in 
July 2014, 93 aliquots from such selected serum speci-
mens were transported to the CDC for detection of RuV 
RNA and genotyping.
Figure 2
Distributions of notified rubella outbreak cases, Romania, 































































A. Monthly distribution of notified (N=24,627) and serological-
ly-confirmeda (N=6,182) rubella cases























































Total RNA was extracted from NP swabs with the 
Nucleospin Viral RNA kit (Macherey, Germany) accord-
ing to the manufacturer’s instructions, except that 20 
µL of proteinase K (20 mg/mL) was added in the lysis 
step and the RNA was eluted in 30 µL RNase-free H2O. 
RNA was also isolated from tissues (lung, kidney, 
spleen, lens, liver, brain, and thymus) from a deceased 
infant with CRS using TRIzol (Invitrogen, US). Extracted 
RNAs were stored at –70 °C.
For RNA extraction from sera shipped to CDC, the 
Qiagen ViralAmp RNA Mini kit (Qiagen, Valencia, CA) 
was used according to the manufacturer’s instructions. 
Detection of rubella virus RNA
In Romania, two detection methods were used to 
detect rubella RNA in the clinical samples. Prior to 2012 
a nested RT-PCR assay [21], which amplified a 143-nt 
region in the E1 coding region, was performed using 
GoScript Reverse Transcriptase and GoTaq Flexi DNA 
Polymerase (Promega,Madison, WI, US) according to 
the manufacturer’s instructions, followed by gel elec-
trophoresis. In 2012 a real-time RT-PCR assay for RuV 
RNA detection using the SuperScript III Platinum One-
Step Quantitative RT-PCR System (Invitrogen, US) [22] 
was implemented. 
At CDC, a TaqMan real-time PCR assay targeting a 154 
nt region near the 5’ end of the rubella genome and the 
same SuperScript kit was used (data not shown).
Genotype determination
All genotyping assays were targeted to the RuV E1 cod-
ing region which contains the 739-nt region recom-
mended by WHO for RuV genotyping. Generation of 
genotyping templates using RNAs from NP swab and 
tissue samples was performed by conventional RT-PCR 
reactions with the Qiagen OneStep RT-PCR Kit (Hilden, 
Germany) as described in Namuwulya et al. [11], except 
that the primers for the 5’ fragment were replaced by 
Figure 3































































a Confirmed cases included 88 pregnant women and 5,820 other patients with rubella symptoms, as well as 274 patients suspected of 
measles but who, after being found negative for measles IgM, were found positive for rubella IgM.
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primers 8656F (5’-CCCCACCGACACCGTGATGAG-3’) and 
9182R (5’-CGTGGATCCACTCGGGGATTT-3’). RNAs from 
sera which were positive by real-time RT-PCR were used 
as templates in one or more of three nested RT-PCR 
assays using specific primers pairs (Table). The nested 
assay 1 was used initially; samples that tested nega-
tive in this assay were subsequently tested using the 
assays 2 and 3.
Sequences derived from assays 2 and 3 were combined 
to obtain the 739-nt sequence. All genotyping nested 
RT-PCR assays were performed with the Superscript 
III One-Step RT-PCR System with Platinum Taq High 
Fidelity DNA polymerase kit (Invitrogen) modified by 
the addition of betaine (Sigma, St. Louis, MO) to a final 
concentration of 1M. Cycling conditions for the first 
round consisted of one cycle of 30 min at 55 °C, 2 min 
at 94 °C, and 40 cycles of 10 s at 94 °C, 15 s at 55 °C, 
and 1 min at 68 °C. For the second round, 1 µL of the 
first round PCR was transferred and the 30 min at 55 °C 
RT step was eliminated. Negative and positive controls 
were carried through both rounds and master mix prep-
aration and template addition were strictly separated. 
To sequence the DNA templates, the PRISM BigDye 
Terminator v3.1 Ready Reaction Cycle Sequencing kit 
(Applied Biosystems, Foster City, California) was used 
on a PRISM 3100-Avant Genetic Analyzer (Applied 
Biosystems).
Phylogenetic analysis
The Romanian sequences were genotyped using 
the method recommended by the WHO [1]. GenBank 
accession numbers for the Romanian sequences are 
KP903737, KP903738, KP941058–62, KR021370–9 
and KR054415–24. For phylogenetic analysis, an align-
ment was created and comprised 19 sequences from 
the 2011–2012 outbreak, three genotypes 1E and 1G 
sequences from the 2003–2004 outbreak, the 1E, 1G, 
and 2B WHO reference virus sequences and selected 
sequences from different parts of the world (26 2B 
sequences (2005–2014), seven 1G sequences (2003–
2008) and two 1E sequences (2001–2003)). Searches 
to select the representative global strains were per-
formed with basic local alignment search tool (BLAST) 
[23] and the selection was based on the degree of nt 
sequence homology with data from the Romanian out-
breaks (≥ 99% identity), geographical distribution and 
collection date. Phylogenetic analysis was performed 
with the programme RAxML v8.00 [24] and the result-
ing tree was edited with the FigTree v1.4.2 programme 
[25] and the Inskape [26] programme for scalable vector 
graphics editing. The genetic distances were computed 
using the maximum-likelihood inference with general-
ised time-reversible (GTR) model of nt substitution and 
gamma model rate heterogeneity.
Figure 4
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IgG-: IgG negative; IgG+; IgG positive; IgM-: IgM negative; IgM+: IgG positive.
The boxes shaded in light blue, in the respective 2nd sample and in overall result rows, highlight samples with evidence of seroconversion.
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Figure 5
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 RVs/Bistrita Nasaud.ROU/45.11 KR021374































































Romanian sequences from 2003 are highlighted in yellow (1E) and green (1G) while those from 2011–12, are highlighted in blue (2B lineage 1), and red (2B lineage 
2). The sequences are according to the World Health Organization recommended standard 739-nt window in the envelope (E)1 coding region of the rubella virus 
genome, and are compared with WHO reference strains (in bold) and representative sequences from RuV genotypes 1E, 1G, and 2B.
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Results
Rubella incidence in Romania
After the year 2000, the incidence of rubella in Romania 
decreased following the 2003–2004 epidemic, from 
218.5 cases per 100,000 population in 2004 to 1.6 
in 2010 (Figure 1). In April and May of 2011, sporadic 
cases were notified in the south and south-east of 
the country. Subsequently in September, the outbreak 
started in the north-west, and spread further so that 
by the end of 2011 the total number of notified rubella 
cases amounted to 3,815 cases (18.2/100,000 popula-
tion). In 2012, the whole country had become affected 
with 20,812 cases notified in that year (97.5/100,000). 
Description of the rubella outbreak
From September 2011 to December 2012, a total of 
24,627 cases were notified, 6,182 were confirmed 
(based on detection of IgM antibody), 18,442 were 
probable (based on an epidemiological link to a labora-
tory-confirmed case) and three were possible. Overall, 
41.1% (n=10,134) of cases were of female sex and 
the median age was 18 years (range: <1–65), with the 
majority of cases (n=16,245) in the 15 to 19 year-old age 
group (Figure 2 A and B). Of all notified cases, 24,067 
cases (97.7%) reported no history of vaccination, 528 
cases (2.1%) reported one dose of MMR vaccine, and 
23 cases (0.1%) reported two doses (vaccination his-
tories were self-reported). For case-patients reporting 
vaccination, 114 (19.5%) were laboratory confirmed and 
437 (80.5%) were considered probable by epidemiolog-
ical link to laboratory-confirmed cases [15].
Serological analysis
Between September 2011 and December 2012, aside 
from sera obtained from 314 pregnant women (which 
are further described below), 9,301 serum samples 
were collected from possible cases of rubella and 
tested for the presence of rubella-specific IgM anti-
bodies. Of these, 5,820 cases were positive for rubella 
IgM-specific antibody. Cases were from all parts of the 
country (Figure 3). Of the 3,481 IgM-negative serum 
samples, 1,726 (49.6%) were collected within 3-days 
post-rash onset. 
Serum samples received via the national measles sur-
veillance programme, which were negative for measles 
specific IgM were also tested for rubella IgM. Between 
September 2011 and December 2012, 274 (30.3%) of 
the 832 measles IgM-negative serum samples, were 
positive for rubella-specific IgM.
Rubella in pregnant women and congenital 
rubella syndrome cases
Sera from 314 pregnant women with clinical symptoms 
of rubella or known to have been exposed to rubella 
were tested for rubella-specific IgM and IgG antibodies. 
In a first respective serum sample, 232 pregnant 
women tested negative or indeterminate for IgM and 82 
tested IgM positive. The 232 IgM-negative or indetermi-
nate women consisted of 74 women negative for both 
IgM and IgG, 155 IgM-negative IgG-positive women, 
and three IgM-indeterminate IgG-negative women. The 
82 IgM-positive pregnant women comprised 18 women 
testing IgM positive IgG negative and 64 testing IgM 
positive IgG positive (Figure 4). 
Follow-up samples for further laboratory confirmation 
could not be obtained for all pregnant women, how-
ever 12 women with negative or indeterminate IgM 
results were retested on a second sample received 14 
days after the first. Six of these 12 women were ini-
tially among the 155 IgM negative IgG positive women, 
three were initially IgM indeterminate IgG negative, 
and three were initially part of the 74 women nega-
tive for both IgM and IgG. The first six women’s tests 
remained unchanged in the second sample (i.e. still 
IgM negative, IgG positive, and with an intermediate 
IgG avidity), while for the latter six there was evidence 
of seroconversion, as they tested positive for both IgM 
and IgG in the second sample.
In total, 88 pregnant women were found to have rubella 
specific IgM-antibodies. The remaining rubella IgM-
negative sera were subsequently tested for measles-
specific IgM antibodies and 12 pregnant women were 
determined to be measles cases.
Overall, the number of women who tested positive for 
rubella-specific IgG only (i.e. IgM negative, IgG posi-
tive) amounted to 155. All had IgGs tested for avidity, 
and 149 were found with high avidity IgG antibodies, 
while six had intermediate avidity IgGs. 
Of the total 88 IgM positive pregnant women, six could 
be confirmed as rubella cases by evidence of sero-
conversion in the second serum sample. For the 64 
IgM-positive women who were IgG positive in the first 
sample, IgG avidity testing was conducted, whereby 47 
had low and 17 intermediate avidity IgG, confirming pri-
mary rubella infection. Because a second serum sam-
ple could not be obtained from 18 women with initial 
IgM positive IgG negative results, IgG avidity testing 
was not possible for these persons. Taking into account 
their symptoms and the epidemiological context how-
ever, they were nevertheless included as outbreak 
cases. 
When available, IgG avidity was used as a complemen-
tary test to the IgM antibody results, to determine the 
possible timing of contracting rubella. Based on this 
approach, it was estimated that 25 pregnant women 
(28.4 %; 25/88) were likely infected during the first tri-
mester. A total of 14 pregnancies were terminated.
Serum samples from 137 infants suspected of having 
been exposed to RuV during fetal development were 
collected, 38 were IgM positive. In addition, RNA was 
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also collected from a stillborn infant. Combined with 
clinical criteria, 27 infants were laboratory-confirmed 
to be CRS by IgM and IgG testing, while the stillborn 
was confirmed to have been infected by RuV using PCR. 
The other 11 infants were identified to have congenital 
rubella infection by an IgM-positive test at birth, and 
an epidemiological link (the mother was confirmed 
with rubella infection during pregnancy) but without 
observable defects. Such children are not followed-up. 
Of 28 infants with CRS, one was a stillbirth and 11 died 
after birth.
Formalin-fixed, paraffin-embedded (FFPE) tissue speci-
mens obtained from one confirmed child with fatal 
congenital rubella autopsy were submitted to the CDC 
for additional studies (histopathological and immuno-
histopathological evaluation) [27]. 
Reverse transcription-polymerase chain 
reaction and genotyping
In May of 2011, two sporadic rubella cases in Bucharest 
were confirmed. Both cases occurred three months 
before the outbreak was recognised and had no recent 
history of travel. A virus sequence from one of these 
sporadic cases (RVs/Bucharest.ROU/18.11) was deter-
mined to be genotype 2B. Between May 2011 and 
December 2012, 68 NP swabs were collected from 
cases occurring in 21 of 42 districts. Thirty-three 
(48.5%) swabs were positive for RuV RNA by either the 
nested or real-time RT-PCR assay. Of these, PCR tem-
plates for genotyping were generated from 11 swab 
samples (36.4%). 
In addition, RNAs from necropsy tissues (lung, kidney, 
spleen, liver, brain, thymus and lens) from one case 
were positive for rubella by real-time RT-PCR and RNA 
from the kidney was used to genotype the virus. 
RNA was also extracted from 93 IgM-positive sera 
which were collected three days after rash onset or ear-
lier. Of these, rubella RNA was detected by real-time 
RT-PCR in 20 sera (21.5%); the average cycle threshold 
value was 37 of 40 cycles (range: 35.7–39). Genotypes 
were determined from seven sera (7.5%). Three of the 
RNAs derived from serum were amplified by nested 
primers set 1 and four required the amplification of 
both the nested primer sets 2 and 3 to obtain the 739-
nt sequence. 
In total, 19 sequences were obtained from rubella 
cases between May and December 2012, representing 
samples from 10 distinct districts (Figure 3). The geno-
type of all the sequences was determined to be 2B by 
comparison to the WHO reference sequences (data not 
shown).
In order to compare the sequences from the 2011–
2012 outbreak to earlier sequences from Romania and 
sequences of the same genotypes retrieved world-
wide, a phylogenetic tree of genotypes 1E, 1G, and 2B 
is shown (Figure 5). The 2003 1E and 1G sequences (in 
yellow and green in Figure 5; Robert Koch Institute, 
Berlin) from two Romanian cities, Bucharest and 
Prahova, were found in the same clusters as viruses 
from other European countries from the same time 
period (e.g. for 1E, RVs/Angers.FRA/36.03; for 1G, RVi/
Minsk.BLR/52.04/2). The 2B sequences from the 2011–
2012 Romanian outbreak assort into two lineages with 
3.11–3.92% nt (23–29 nt) difference between the two 
lineages. Lineage 2 appeared to have had a smaller 
geographical range, being found in Bucharest and two 
other districts, while lineage 1 was found in Bucharest 
and seven additional districts (Figure 3). Lineage 1 
contains 12 of the Romanian sequences from 2011 and 
2012 as well as 2010–2014 sequences from different 
areas of Asia including Japan, Taiwan and Vietnam. One 
of three sequences from Great Britain in this cluster 
Table
Primer sequences for three nested reverse transcription-polymerase chain reaction genotyping assays

























PCR: polymerase chain reaction.
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(RVs/Isle of Man.GBR/03.12) was epidemiologically 
linked to an importation from Romania (Kevin Brown, 
personal communication, 25 January 2016). This line-
age descends from sequences from South America and 
India detected from 2006 to 2009. Lineage 2 contains 
seven of the Romania sequences, including a sequence 
from a sporadic case early in 2011 (RVs/Bucharest.
ROU/18.11) and six from 2012. Lineage 2 also contains 
another import into Great Britain from Romania (RVs/
Edinburgh.GBR/06.12) (Kevin Brown, personal commu-
nication, 25 January 2016). Other sequences from the 
same time period as the Romania outbreak in this line-
age are from Tunisia, and Great Britain, with two older 
sequences from Canada (2009) and India (2005).
Discussion
Rubella is usually a mild benign disease, but due to its 
devastating effects in pregnancy, control and elimina-
tion programmes have been instituted in many coun-
tries; the disease has been eliminated by immunisation 
programmes in several countries, including those in the 
WHO Region of the Americas [28-31]. Universal rubella 
vaccination of one year-old infants was implemented in 
Romania in 2004; however, outbreaks continue to occur 
following a typical 6 to 9 year epidemic cycle. The total 
number of cases notified in Europe since 2007 varied 
from 26,827 in 2007 to 4,767 in 2010 then increased 
to 8,318 in 2011 and to 26,014 in 2012 [30,32]. In 2011, 
97% of the rubella cases in Europe were reported from 
Poland and Romania [33], although it has to be taken 
into account that rubella surveillance has not been 
implemented in all European countries. During the 
2011–2012 outbreak in Romania, cases occurred in all 
the districts of the country, amounting to 24,627 noti-
fied cases, most of which were unvaccinated (97.7%). 
The majority of cases were 15 to 19 year-olds who were 
missed by the current vaccination strategy (the MMR 
coverage among adolescents is not routinely moni-
tored in Romania). The 2011–2012 outbreak resulted in 
the birth of 28 children with CRS, including 11 deaths 
and one stillbirth.
In Romania, rubella surveillance requires laboratory 
detection of IgM-specific antibody in serum collected 
from each sporadic case and the first cases from 
rubella outbreaks [11]. A limitation of rubella IgM tests, 
however, is that the IgM response may not have devel-
oped for a serum collected within the first 72 hours 
after rash onset, resulting in a false-negative result 
[22,34]. In the 2011–2012 outbreak 3,481 serum sam-
ples were negative for specific rubella IgM, but 49.6% 
of the negative sera were collected too close in time to 
the onset of rash; therefore, the total number of sero-
logically-confirmed cases (n = 6,182) in the outbreak 
was likely underestimated.
In addition to serological testing, molecular detec-
tion of RuV RNA is useful for the further confirmation 
of rubella infection, especially in the five days after 
rash onset [22]. Moreover, sequence information can 
be obtained and used to differentiate between vaccine 
and wild-type infections and, in combination with 
well-established baseline genetic and epidemiological 
data, to identify indigenous or imported viruses. The 
ideal samples for rubella isolation and detection are 
NP specimens, collected as soon as possible after the 
onset of symptoms (< 5 days after rash onset), but col-
lection of samples for virological surveillance can be 
challenging due to the logistics of storage and trans-
port. Nevertheless, we were able to obtain 68 swabs 
and genotype 11 samples. In addition, although sera 
are not optimal specimens for viral detection due to 
the low amounts of viral RNA present, RuV RNA was 
detected in 21.5% of IgM positive serum samples col-
lected close to symptom onset, while genotypes were 
obtained from 7.5%. These numbers are in good agree-
ment with a previous study of RuV RNA in sera in which 
26% of sera samples were real-time PCR positive and 
12% yielded genotypes [35].
Genetic information obtained from the 2011–2012 out-
break in Romania revealed that it was driven by two 2B 
lineages with an average of 3.5% nt difference, which 
overlapped both temporally and geographically. Data 
from other countries have shown that co-circulation of 
multiple RuV lineages of one genotype within a country 
is quite common [36,37]. Lineage 1 Romanian outbreak 
sequences, which were most similar to those of viruses 
from south-east Asia, were detected from late 2011 
through the spring of 2012 while lineage 2 sequences, 
which were most similar to a viral strain from north-
ern Africa, were detected in May 2011 from one of 
the sporadic cases and then from early 2012 through 
December of 2012. In addition, analysis of sequence 
data confirmed that viruses which were identified by 
epidemiological data as exportations to Great Britain 
were identical to viruses from Romania.
The viruses of genotypes 1E and 1G detected in 
Romania in the previous outbreak in 2003 were not 
detected in the 2011–2012 outbreak and no sequences 
from Romania are available from the intervening time 
period; therefore, it is not possible to know when the 
genotype 2B viruses entered the country. The viruses 
in the 2011–2012 outbreak may have been circulating 
in Romania before the outbreak. However, they may 
have been introduced by recent importation events, as 
would be suggested by the high degree of sequence 
similarity with viruses from approximately the same 
time period (2011 to 2013) detected in other parts of 
the world such as Japan, Vietnam and Taiwan (Figure 
5). The very low incidence of rubella in the two to 
three years before the outbreak is consistent with this 
hypothesis. In addition, the approximate nine month 
gap that elapsed between the first and second detec-
tions of lineage 2 suggests that there may have been 
two separate introductions of this lineage. Gaps in 
viral surveillance for rubella both regionally and glob-
ally limit the ability to use genetic data for identifying 
the source of a particular lineage. It is clear, however, 
that a shift occurred in the RuV genotypes over time 
from genotypes that were common in other European 
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countries (1E and 1G) to the 2B genotype that was pre-
viously found primarily in other parts of the eastern 
hemisphere [1]. Such genotype shifts have been docu-
mented in other countries such as China [35] and Brazil 
[38].
This is the first report of RuV sequences from Romania. 
Documenting virus genotypes is one of the essen-
tial criteria for tracking the progress of elimination of 
rubella in the WHO European region [39]. Thus, deter-
mining the endemic RuV genotype baseline is neces-
sary. However, as shown here circulating genotypes 
can change over time and ongoing surveillance is nec-
essary to provide up-to-date information. 
In order to reach the goal of endemic rubella elimina-
tion and, thus, prevent CRS cases such as those that 
resulted from the 2011–2012 outbreak, it is necessary 
to achieve and sustain high vaccination coverage > 95% 
(the women in reproductive age who were born before 
2004 should be better informed on the risks of rubella, 
encouraged to get vaccinated and women in child-
bearing age checked for immunity to rubella prior to 
pregnancy) supported by high-quality surveillance 
including epidemiological, serological and molecular 
studies. This process will include the development of 
case-based epidemiology investigations to identify 
importations and prevent secondary transmissions 
especially in countries such as Romania where rubella 
virological surveillance is not yet well established.
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